RE:RE:RE:RE:RE:RE:RE:Glad to see Morningstar numbers creeping up @Smokey .... you're quoting a July 2021 article on Abbott & Quidel shuttering Covid-19 testing operations???.. over 9 months ago?
Things obviously change as COVID TESTS DROVE THEIR REVENUES LAST YEAR & STARTING THIS YEAR!!! All from February 2022, March 2022 and April 2022... not July 2021….
They’ve obviously re-ramped production as much of the revenues are driven by Covid… and significant growth in these tests
Abbott First Quarter 2022 Earnings (April 20, 2022) https://www.prnewswire.com/news-releases/abbott-reports-first-quarter-2022-results-301528820.html
- First-quarter sales of $11.9 billion increased 13.8 percent on a reported basis and 17.5 percent on an organic
- Global COVID-19 testing-related sales were $3.3 billion in the first quarter.
- % Covid Sales to Total Sales: 3.3B / 11.9B = 27.7%
- Abbott Laboratories PE Ratio: 29.87 for April 14, 2022
Quidel FY 2021 Earnings (February , 2022)
https://ir.quidel.com/news/news-release-details/2022/Quidel-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results/default.aspx
- Total revenue for 2021 increased to $1,698.6 million, a 2% increase from $1,661.7 million in 2020.
- Revenue for COVID-19 products in 2021 increased 42% to $1,267.0 million, from $891.0 million in 2020.
- Quidel PE ratio as of April 15, 2022 is 6.41. (Mainly because their business is 75-80% Covid-19 Rapid Tests)
Diasorin FY 2021 Earning. ( March 16, 2022)
- DIASORIN BUSINESS MOMENTUM AND THE LUMINEX ACQUISITION DRIVE UP REVENUES, NET RESULT AND CASH FLOW GENERATION IN 2021
- REVENUES: € 1,237.7 million, +40.4% (+41.2% at CER) compared to 2020
- Luminex contributed € 195.0 million to Group revenues: worth mentioning is the strong performance of molecular business on the Covid-19 Aries®
- % Covid-19 Test to Total Revenue: 195M Euros / 1237.7M Euros = 15.75%
- Diasorin PE Ratio: April 2022: 24.84